**Changes in peripheral quantitative computed tomography measured bone density, size and strength in Zimbabwean children with and without HIV over one year: a cohort study**

**Authors**

Cynthia Kahari1,2, Celia L Gregson4, Mícheál Ó Breasail5,6, Ruramayi Rukuni2,7, Tafadzwa Madanhire1,2, Victoria Simms1,2, Joseph Chipanga2, Lynda Stranix-Chibanda8, Lisa K. Micklesfield9, Rashida A Ferrand2,7, Kate A Ward10,11, Andrea M. Rehman1

**Affiliation**

1. Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

2. The Health Research Unit (THRU-ZIM), Biomedical Research and Training Institute, Harare, Zimbabwe

3. Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe

4. Musculoskeletal Research Unit,Bristol Medical School, University of Bristol, Bristol, UK

5. Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Monash Medical Centre, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia

6. Population Health Sciences, Bristol Medical School, 1-5 Whiteladies Road, Bristol, BS8 1NU

7. Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK

8. Child and Adolescent Health Unit, University of Zimbabwe Faculty of Medicine and Health Sciences, Harare, Zimbabwe

9. South African Medical Research Council/Wits Developmental Pathways for Health Research Unit (DPHRU), Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

10. MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK

11. MRC The Gambia Unit at LSHTM, London, UK/The Gambia

**Running title:** pQCT assessed bone accrual in children with HIV

**Corresponding Author:** Cynthia Kahari, PhD

**Address:** The Health Research Unit Zimbabwe (THRU-Zim), Biomedical Research and Training Institute, 10 Seagrave Road, Avondale, Harare, Zimbabwe.

**Email:** c.mukwasi@gmail.com

**Abstract**

Understanding bone accrual in adolescents may inform approaches to improve skeletal health and reduce adult fracture risk. We investigated the effect of HIV on bone mineral accrual assessed by peripheral Quantitative Computed tomography (pQCT). Children with HIV (CWH) on ART for ≥2 years, and children without HIV (CWOH), aged 8-16 years (n=609), had tibial pQCT scans at 0 and 12 months. Linear regression estimated sex stratified differences in change (∆) and mean pQCT bone density (trabecular and cortical), size (total cross-sectional area [CSA]) and strength (SSI) between CWH and CWOH, adjusting for socio-economic status (SES) and orphanhood and incorporating an interaction term for baseline pubertal status (Tanner 1-2[pre/early] vs 3-5[mid/late]). Structural equation modelling tested whether baseline height-for-age-Z-scores (HAZ) mediate the effect of HIV on ∆bone outcomes. CWH were more likely than CWOH to be orphans (44% vs 7%), of lower SES (43% vs 27%) and be stunted (30% vs 8%); but similar in age. At baseline and follow up, CWH had lower trabecular density, CSA and SSI than CWOH. After adjustment, bone density and strength increased similarly in CWH and CWOH. CWH in mid/late puberty at baseline had greater 12 months increases in CSA than CWOH, particularly males (mean difference [31.3(95%CI:-3.1, 65.6) mm2 in mid/late puberty vs. -2.04(-23.8, 19.7) mm2 in pre/early puberty; interaction p-value=0.013]. HAZ mediated the effect of HIV on ∆bone outcomes only in females as follows: indirect pathways from HIV to ∆trabecular density [-1.85(-3.5, -0.2) mg/cm3], ∆cortical density [-2.01(-3.9, -0.01) mg/cm3], ∆CSA [-2.59(-4.7, -0.5) mm] and ∆SSI [-18.36(-29.6, -7.2) mm3]. In conclusion, CWH show bone deficits at follow up. Investigations of bone mineral accrual earlier in life and post-puberty to peak bone mass are needed.

**Keywords:** ANALYSIS/QUANTIFICATION OF BONE, DISEASES AND DISORDERS OF/RELATED TO BONE, EPIDEMIOLOGY

**Introduction**

People living with HIV are at increased risk of fragility fractures, particularly hip fracture (1). Bone mineral density (BMD), size and strength are important determinants of fracture risk (2). Bone health in later life reflects both bone accrual in childhood and adolescence and bone loss in adult years. Understanding factors that influence bone accrual may inform approaches to improve skeletal health, for example through maximising acquisition of peak bone mass (PBM) to reduce future adult fracture risk. Most studies investigating BMD by dual energy x-ray absorptiometry (DXA) have reported lower BMD in children living with HIV (CWH) than in children without HIV (CWOH) (3–5). In a cross-sectional analysis, we previously demonstrated lower bone size and predicted bone strength in CWH compared to CWOH; deficits were larger in the later stages of puberty, suggesting lasting effects into early adulthood (6). Underlying aetiological mechanisms remain unclear, and furthermore, it is uncertain whether CWH ‘catch-up’ with their uninfected counterparts as the skeleton matures. (7). Treatment of HIV is associated with poor bone outcomes. In addition, traditional factors that contribute to poor growth and bone accrual such as low dietary calcium, low physical activity and social deprivation, are common in CWH (7). Although data on bone development in CWH has recently begun to emerge from sub-Saharan Africa where 90% of CWH live (8), available studies to date have either largely used DXA, which only measures two-dimensional areal bone density (3–5,7,9), or have been cross-sectional in study design (10).

Peripheral quantitative computed tomography (pQCT) uses very low-dose radiation to measure volumetric BMD and bone geometry of cortical and trabecular bone compartments. The skeleton constitutes 80% cortical bone and 20% trabecular bone (11). Use of pQCT offers an opportunity to increase our understanding of how HIV affects trabecular and cortical bone development during puberty.

Longitudinal data are necessary to understand bone development, particularly in the context of HIV-associated growth impairment (3,12). Longitudinal studies assessing the effect of HIV on bone mineral accrual from sub Saharan Africa are lacking despite that 90% of CWH are living in this region. We have previously demonstrated that stunting disproportionately affects CWH compared to CWOH in Zimbabwe, where 32% CWH, age 8 -16 years, are stunted (7). It is unclear how much of the effect of HIV on bone accrual is explained by, and therefore proportionate to, impaired longitudinal growth. Hence, this study aimed to use pQCT to study a paediatric population in sub-Saharan Africa and determine the effect of HIV on the change in pQCT measured bone density, size and strength over a 12-month period. We also determined to what extent impairment in longitudinal growth explains any detrimental effects of HIV on pQCT-assessed bone outcomes.

**Methods**

**Study setting**

A cohort study, the IMpact of Vertical HIV infection on child and Adolescent Skeletal development (IMVASK), with two visits 12 months apart, was conducted as per published protocol (ISRCTN12266984) (6,7,13). Perinatally infected CWH attending either of the two main public hospitals in Harare, Zimbabwe, were quota sampled, stratified by sex and three-year age band (8-10, 11-13, 14-16 years). Perinatal infection was defined as HIV acquired since birth and not via blood transfusion or sex. Inclusion criteria were being established on anti-retroviral therapy (ART) for at least 2 years and being aware of their HIV status. Stratified random sampling was used to recruit CWOH from three primary and three secondary schools randomly selected from the 109 primary schools and 44 secondary schools serving the population residing within the same catchment area as the hospitals. The number of children selected from each school was proportional to school size. A random number sequence was generated, and school registers were used to select participants of similar age and sex as the CWH using the same quota- based approach of 50 male and 50 female in each of the three age strata. CWOH were tested for HIV to confirm their status and excluded if positive. Those with acute illness requiring hospitalization, and who had no parental consent were excluded.

**Study Procedures**

Baselinedata were collected from May 2018 to January 2020, and follow-up from May 2019 to January 2021. Study procedures at the baseline and follow-up visits were the same, as previously described (7,13).Questionnaires, completed by the parents/guardians, were used to collect demographic and clinical data including age, sex, orphanhood, socio-economic status (SES), medical history, physical activity patterns and dietary data concerning calcium and vitamin D intake. SES was derived using the first principal component combining a list of factors (number in household, head of household age, highest maternal and paternal education levels, household ownership, monthly household income, access to electricity, water supply, household sanitation and ownership of a fridge, bicycle, car, television, and/or radio) and was split into tertiles for analysis. Physical activity, assessed using the International Physical Activity Questionnaire (IPAQ) short version (14), classified participants into low (<600 metabolic rate (MET) minutes per week), moderate (600 to 3000 MET minutes per week) and vigorous intensity (3000 MET minutes per week). A diet and nutrition assessment food frequency tool, validated in India and Malawi (15) and then adapted to the Zimbabwean context with international guidelines applicable to sub-Saharan Africa, was used to quantify dietary calcium and vitamin D intake (16). The mandatory fortification of oils and margarine with vitamin D in Zimbabwe was included in the adaptation. Daily dietary calcium intake was classified as very low (<150mg/day), low (150-299mg/day) and moderate (300–450 mg/day). Daily dietary vitamin D intake was classified as very low (<4.0mcg/day), low (4.0-5.9mcg/day) and moderate (6.0-8.0mcg/day) (16).

Puberty was assessed by a trained study nurse or doctor using Tanner staging. For males, testicular volume, penile size (length and circumference) and pubic hair growth (quality, distribution and length) were assessed. For females, breast growth (size and contour) as well as pubic hair growth and age of menarche were assessed. Testicular, breast and penile growth were graded from 1-5 based on Tanner descriptions (17,18). Where there was a discordance between the indicators, testicular and breast development stage respectively for males and females were used to assign Tanner stage. Participants were grouped into Tanner stages 1 and 2 (pre/early puberty) and Tanner stages 3 to 5 (mid/late puberty). A mean of 3 standing height measurements, to the nearest 0.1cm, using a Seca 213 stadiometer (Hamburg, Germany) and a mean of 3 weight measurements, to the nearest 0.1kg, using a Seca 875 weight scale (Hamburg, Germany) were obtained. As World Health Organization data for WAZ are not available beyond 10 years of age (20), weight and BMI Z-scores were generated using external growth standards (from the UK in 1990) (19). Height Z-scores were generated in the same way (19); as a validation step Height Z-scores were generated using height measurements from the HIV negative children recruited in this study, as reference data. Height-for-age Z-score <-2, weight-for-age Z-score <-2, and low weight-for-height BMI Z-score <-2 were used to define stunting, underweight and wasting respectively (19,21). CD4 cell count was measured using a PIMA CD4 (Waltham, Massachusetts, USA) machine and HIV viral load using a GeneXpert HIV-1 viral load platform (Cepheid, Sunnyvale, California, USA).

**pQCT scan acquisition at baseline and follow-up**

Non-dominant tibial pQCT scans were performed using a single XCT 2000TM (Stratec Medizintecknik, Pforzheim, Germany), with voxel size 0.5 x 0.5 mm and slice thickness 2 mm (CT scan speed 30 mm/s; scout view scan speed 40 mm/s). At each visit, tibia length (in millimetres) was measured once, as the distance from the distal medial malleolus to the tibial plateau. Scan sites were determined as a percentage of tibia length, with the exact position determined by scout view placement of a reference line on the growth plate, or on the end plate for those with fused growth plates (22). As long bones grow in length, the growth plate moves upward and the wider metaphysis is reshaped into a diaphysis by continuous resorption by osteoclasts beneath the periosteum (23). To allow for consistency of a scan site the reference line was placed at the growth plate in those children whose end plate and growth plate were not yet fused. If the growth plates were not fused, the reference line was placed on a line dissecting the growth plate along the medial line. If a growth plate had fused during the follow up interval, the reference line was placed on the end plate. Scan sites were at 4% (trabecular vBMD) and 38% (cortical vBMD) of the measured tibial length. Other measurements included 4% and 38% total cross-sectional area [CSA], 38% cortical thickness and 38% stress strain index [SSI]. The same software (version 6.20 Stratec Medizintechnik) was used for image processing and analysis at both baseline and follow-up.

A phantom was scanned daily for quality assurance. To assess reproducibility, 30 participants were scanned twice after repositioning. Short term precision (Root Mean Square % CV) was 1.26% for trabecular vBMD, 0.37% for cortical vBMD, 2.08% for 4% total CSA and 0.93% for 38% CSA. One radiographer qualitatively assessed and graded all pQCT images for movement artefacts from 0 to 3: (0) none, (1) slight streaking, (2) moderate streaking and (3) scan unusable. Scans graded as a 3 were excluded from analysis. Baseline and follow-up scans were assessed to check that scan positioning at baseline and follow-up were consistent. In addition to movement artefacts, other scan errors such as disagreement in the side scanned (left or right tibia) or in the positioning of the reference line placement (growth plate or end plate) between baseline and follow-up scans were reasons to exclude participant scans from analyses.

**Ethical considerations**

This study was approved by the Parirenyatwa Hospital and College of Health Sciences joint research ethics committee (JREC/123/19), the Biomedical Research and Training Institute Institutional Review Board (AP150/2019), the Medical Research Council of Zimbabwe (MRCZ/A2494) and the London School of Hygiene and Tropical Medicine (17154) Ethics Committee. Written informed consent and/or age-appropriate assent was obtained from parents/guardians and participants.

**Statistical analysis**

Statistical analyses were performed using Stata version 17 (Stata Corporation Inc., College Station, TX, USA). Data were cleaned and checked for consistency and outliers. Primary outcomes were annualised mean 4% ∆ trabecular and 38% ∆ cortical vBMD (mg/cm³), 4% and 38% ∆ CSA (mm²), 38% ∆ cortical thickness (mm) and 38% ∆ stress-strain index (SSI) (mm4). Annualised changes of pQCT bone outcomes were defined as the pQCT bone outcomes at follow up minus the pQCT bone outcome at baseline, divided by number of day between the baseline and follow up visits and multiplied by 365.25. All analyses were stratified by sex as bone accrual rates differ between males and females (24). Independent t-tests were used to compare group means for continuous data and chi-squared tests were used for categorical percentages. Linear regression (with robust standard errors) was used to estimate mean differences (presented with 95% CI) between CWH and CWOH. Adjustments were made for SES in tertiles (25), and orphanhood (7). Potential differences in the effect of HIV on ∆bone outcomes by pubertal status were tested by incorporating an interaction term for baseline binary pubertal status (Tanner 1 & 2 vs Tanner 3, 4 & 5). Structural equation modelling (SEM) for mediation analysis was used to evaluate whether the effect of HIV infection on change in bone outcomes was mediated first by internally generated baseline height Z-scores and secondly by internally generated baseline tibia length Z-scores at baseline. Structural equation modelling was used, irrespective of the overall association between HIV and the pQCT bone outcomes since it is possible for an exposure to exert an effect on an outcome indirectly through a mediator even if one cannot establish evidence of an association through a hypothesis test, for a total effect of an exposure on an outcome (26). The structural equation models used linear regression and were adjusted for SES and orphanhood.

**Results**

**Study population**

At baseline 609 participants, 303 CWH (151 [49.8%] male and 152 [50.2%] female), and 306 CWOH (151 [49.8%] male and 152 [50.2%] female) were recruited, and 492 (80.7%) participants, 244 CWH (125 [51.2%] male and 119 [48.8%] female), and 248 CWOH (122 [49.2%] male and 126 [50.8%] female)) had a follow-up visit (Supplementary Figure 2). In the complete case analysis, 419 (68.8%) participants had usable pQCT scans at both baseline and follow-up and were not missing covariate data. The 190 (31.2%) participants (108 CWH and 82 CWOH) not included in analyses were similar to those included in terms of age, sex, height, weight, pubertal stage, SES, physical activity levels, calcium and vitamin D intake; (Supplementary Table 1). Eleven of 419 children (3%) underwent complete fusion of epiphyses and had a change in reference line placement from the growth plate to end plate.

 At baseline, males were aged mean 12.3 (standard deviation [SD] 2.5) years and females 12.4 (SD 2.5) years with no difference by HIV status (Table 1). Follow-up was challenged in 2020-2021 by national travel restrictions due to COVID-19 lockdown. Between-visit duration was on average 66 days longer among CWH compared to CWOH; therefore, at follow-up CWH were older than CWOH (Supplementary Table 1). Most males [n=132 (62%)] were in Tanner stages 1 or 2 at baseline, while fewer than half were so at follow-up [n= 94 (44%)]; this did not differ by HIV status. More female CWH were in Tanner stage 1 and 2 compared to CWOH (at both baseline and follow-up) (Table 1, Supplementary Table 1). Having one or both parents deceased was more common among CWH, compared to those without HIV (42% vs 7% in males; 46% vs 6% in females, Table 1). CWH were more likely to have a lower SES than CWOH (43% vs 25% in males; 42% vs 29% in females). Dietary calcium intake and levels of physical activity were generally low, with no difference by HIV status (Table 1).

Both height and weight were lower in CWH than CWOH, but during follow-up CWH experienced greater absolute gains in height compared to CWOH (Table 1). At baseline, male and female CWH were 6cm and 8cm shorter than CWOH, respectively and more likely to be stunted (33% vs 7% [males]; 26% vs 9% [females]). Stunting prevalence increased slightly at follow-up when CWH were more likely to be stunted than CWOH (43% vs 9% [males]; 33% vs 11% [females]) (Supplementary Table 2). Although overall the study population gained weight during follow-up, the proportion who were classified as having low weight-for-age increased; at follow-up this was more likely in CWH than CWOH (35% vs 14% in males; 27% vs 7% in females) (Supplementary Table 2). During follow-up a greater proportion of CWH than CWOH advanced in Tanner stage, 62% vs 49% in males and 66% vs 59% in females (Table 1).

**The effect of HIV on pQCT bone outcomes**

At baseline, all CWH had lower distal trabecular density, lower distal and diaphyseal tibial CSA and lower predicted bone strength (38% SSI) than CWOH, while diaphyseal cortical density and thickness were comparable by HIV status, in both males and females (Table 2); these findings persisted at follow-up and remained robust to adjustment for SES and orphanhood (Table 2). In analyses of annualized change in bone parameters, adjusted for SES and orphanhood, the annual change in pQCT measures was similar by HIV status (Table 2). Baseline pubertal stage appeared to modify the effect of HIV on growth in bone size, specifically distal tibial CSA in males, such that in late puberty male CWH had a greater increase in tibial CSA than CWOH, with a mean adjusted difference of 31.3 mm2 [95%CI -3.1, 65.6; p=0.074; interaction p=0.013] (Figure 1, Table 3). In females the same pattern was seen at the diaphyseal site for tibial CSA (rather than the distal site in males), such that female CWH in late puberty at baseline had greater increases in bone size than CWOH. No evidence was detected for an interaction between pubertal stage and HIV for bone density or strength measures.

**The effect of HIV on change in pQCT bone outcomes mediated by height for age z-scores.**

In females, there was some evidence that the effect of HIV on annualized change in pQCT bone outcomes was mediated via HAZ (Table 4). In both males and females, there was strong evidence of an association between HIV and lower baseline HAZ (the mediator). The effect of HIV on HAZ was β -0.88 (95%CI -1.19, -0.57); p<0.001 in males, and -0.90 (-1.24, -0.57); p<0.001 in females. In males, there was no evidence of an indirect effect of HIV on change in pQCT outcomes via HAZ and hence no evidence for mediation by linear growth, except for ∆cortical density only (-3.19 (-5.55, -0.82); p=0.008) which was completely mediated by HAZ. In females, there appeared to be an indirect effect of HIV via HAZ on ∆trabecular density, ∆cortical density and ∆predicted bone strength (SSI), whilst no evidence for a direct effect of HIV on these bone outcomes was seen.

In sensitivity analyses (a) modelling change in bone outcomes adjusted for duration of follow-up, findings were unchanged, (b) excluding 11 children who underwent epiphyseal fusion, findings were unchanged, and (c) assessing whether tibial length Z-Score mediated the effect of HIV in bone outcomes differently from height Z-Score, we identified broadly consistent patterns, although indirect effect estimates were smaller (supplementary table 3).

**Discussion**

To our knowledge, this is the first study to investigate longitudinal changes in detailed pQCT measured bone parameters in CWH in sub-Saharan Africa. The study showed that CWH have consistently lower trabecular bone density, bone size and bone strength than CWOH over one year of follow-up. Our findings suggest that in children aged 8-16 years, puberty modifies the effect of HIV on bone mineral accrual, such that in the later stages of puberty both male and female CWH increase their bone size more than CWOH, although at the end of follow-up, and despite more CWH transitioning pubertal stage, bone size remains smaller in CWH. Furthermore, we have demonstrated there is a mediation effect of height on pQCT bone outcomes in females only, although total effect sizes are similar in males and females.

There were greater increases in height over the one-year of this study in CWH than CWOH. In addition, over the same period, a greater proportion of CWH than CWOH advanced in Tanner stage. We have previously reported pubertal delay in the same cohort (7) and other studies have shown height is strongly determined by pubertal growth (27). Pubertal transition is classically characterised by a ‘growth spurt’ (*i.e.* peak height velocity). The differences in height change in our cohort could be explained by more CWH than CWOH still undergoing pubertal transition from early to late puberty. Despite that, male CWH who were in the later stages of puberty gained more bone size at the 4% site than CWOH; however, male CWH still had lower mean bone size than CWOH at the follow up visit. These results suggest that, although CWH demonstrate a degree of catch-up growth in bone size, as they transition through puberty, this catch-up growth may be insufficient to reach full skeletal potential. These findings are concerning since deficits in bone accrual at the end of puberty are likely to persist into adulthood.

We have shown that CWH still had lower bone outcomes at follow up despite the greater increase in height over the study period. Moreover, we have demonstrated that the effect of HIV on ∆bone size, ∆bone strength and ∆cortical density in females, is due to the indirect effect of HIV on height rather than the effect of HIV on changing bone turnover and mineral accrual. Childhood HIV infection can manifest as stunting (poor linear growth). Our study reports a higher prevalence of stunting in CWH than in CWOH for both males [33% (CWH) vs 7% (CWOH)] and females [26% (CWH) vs 10% (CWOH)]. This is similar to several studies that have assessed growth patterns in African countries which have consistently reported high prevalence of stunting as measured by height for age Z-scores in CWH (12,29–35). In Zimbabwe CWH have higher odds of stunting; eight times greater in those who have acquired HIV in utero, and four times greater in those who have acquired HIV around the time of birth (36). Improvements in growth have been reported in CWH who have an early HIV diagnosis and less severe HIV symptoms or who start ART early (37). However, in Africa, CWH start ART later in life than other parts of the world, often when the disease is already in a more advanced stage, potentially affecting growth (38).

To date, only one other study conducted in Canada has assessed longitudinal changes in pQCT bone outcomes in 31 CWH, which reported no change in pQCT bone outcomes over 2 years; (38), probably because the study was underpowered. Our findings demonstrate lower bone outcomes in CWH than in CWOH at both baseline and follow up, despite evidence of some catch up growth as CWH transition through puberty. Bone formation occurs at a faster rate before the age of 4 years, and during puberty than in any other time of one’s life. Our cohort were enrolled into the study at minimum age of 8 years. It is unclear whether or not the lower bone density size, and strength we observed in CWH is a result of factors influencing bone in the early years of life and whether or not CWH will eventually catchup to their uninfected counterparts.

Combining our results, we hypothesise that the trajectory of skeletal growth for CWH has been preset at a lower trajectory than in CWOH before the age of 8 years possibly even before the initiation of antiretroviral therapy by age 4 years, in the critical window of the first 1000 days of life. Figure 2 illustrates this hypothesis. As the children transition through puberty, it appears that the development of density and strength runs in parallel to CWOH meaning they are growing at the same rate but that the set point has been predetermined by something else earlier in life and by the end of our study’s follow up period, there are still deficits in all parameters of bone. There is evidence of catchup growth as puberty proceeds with bone area increasing to accommodate height growth. Whether or not, that is sufficient to enable CWH to get back on the trajectory they would have been had they not had HIV is unknown. It is also not known whether it is possible to reset that trajectory through interventions in the early life management of CWH. Moreover, when those children are reaching the end of puberty it is unclear whether children with HIV continue to accrue bone for a longer period of time to an older age than CWOH such that they do achieve the peak bone mass at a later stage. Studies are needed to examine the pattern of growth in later adolescence and timing of the acquisition of peak bone mass in CWH to assess whether deficits in bone and in height are likely to continue through adulthood and increase their risk of fracture.

**Strengths and limitations**

The strengths of this study include the novel use of pQCT’s three-dimensional outcomes to evaluate bone measurements using a large sample. The inclusion of a comparison group of children without HIV, and longitudinal follow-up are also strengths. The participants are likely to be representative of children living in Harare due to our robust sampling methods. The precision results reported in our study are comparable to the expected precision results for pQCT bone outcomes from other authors, suggesting our results are likely not due to scan errors and this is another strength of this study. The use of pQCT may also be considered a potential limitation, as this is not a technique used in clinical practice, which limits the ability to relate our findings to routine clinical practice. There are currently no normative pQCT reference data for children living in sub-Saharan Africa, so it is not possible to determine how our measurements relate to a population norm. There are no validated reference growth database for children living in Zimbabwe or in sub Saharan Africa. In defining stunting, underweight and wasting in this study, the use of growth reference values from British children requires some caution in interpretation as changes in Z-scores may reflect changes relative to UK growth curves (for example timing of puberty), rather than changes in the children under study. This is a limitation of use of external references such as this and WHO standards (which we did not use because they do not cover the age range of our study population for weight) and highlights the importance of collecting independent country-specific references (39).Participants with missing data were excluded to allow structural equation modelling analysis, thereby limiting the number of participants and potentially reducing power in this study. Small numbers within Tanner stage categories limited our ability to test for interaction, as we needed to group participants in different pubertal stages based on numbers within each stage, rather than pubertal biological characteristics for each stage. We assessed reliability of pQCT bone outcomes but not of height and tibia length measurement and therefore we acknowledge this as another limitation of our study. The study was underpowered to assess the relationship between changes in height with changes in bone outcomes over a year, to determine whether changes were proportionate across compartments. Furthermore, the exact timing of peak height velocity could not be established, meaning it is not currently possible to determine whether the differences are delays in growth or persisting deficits in bone accrual. Follow-up of longer than one year may provide further insights into trajectories of bone mineral accrual.

**Conclusion**

Deficits were seen in bone size and strength associated with HIV infection over one year follow-up. CWH gained more height, bone size and bone strength than CWOH over the follow-up period, showing some evidence to support catch-up growth in CWH, but not enough to rectify total deficits in bone density, size and strength. These findings add to information on growth impairment in CWH and have potential implications for fracture risk in adulthood. If bone accrual does not catch up, CWH may be at higher risk of fracture in later life. To better understand trajectories of skeletal development, further research is needed to assess the effect of HIV on bone development in the early years of life as well as to follow-up CWH through to the end of young adult bone accrual.

**Funding statement**

CK was funded by a National Institute of Health Fogarty Trent Fellowship (grant number 2D43TW009539-06). RR is funded by the Wellcome Trust (grant number 206764/Z/17/Z). Global challenges research funding from the University of Bristol, and an Academy of Medical Sciences GCRF Networking Grant (grant number GCRFNG100399) established the sub-Saharan African MuSculOskeletal Network (SAMSON) and provided the peripheral quantitative computed tomography scanner in Zimbabwe for this study. AMR and VS are partially supported by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, which is also part of the European and Developing Countries Clinical Trials Partnership 2 programme supported by the EU (grant number MR/R010161/1). RAF is funded by the Wellcome Trust (grant number 206316/Z/17/Z).

**Conflict of interest**

The authors declare no conflicts of interest.

**Author Contributions**

Conception; CK, AMR, KAW and CLG. Design: CK, KAW and CLG. Data curation: CK, AMR, MO’B, RR and JC. Formal analysis: CK, TM, VS and AMR. Interpretation: CK, AMR, KAW, CLG. Writing- Original draft: CK, CLG and AMR. Writing- Review & editing: CK, CLG, MO’B, RR, TM, VS, JC, LSC, LKM, RAF, KAW and AMR. Supervision: AMR, LSC, LKM, RAF, KAW and CLG. Project administration: CK, RR, JC, RAF and CLG. All authors take responsibility for their contributions as outlined above

**Acknowledgements**

We are grateful to the IMVASK study team who assisted in collecting data for this study and also to the participants (and their parents/guardians) for making this study possible.

**Data sharing statement**

Data sharing: The data that support the findings of this study are available on request from the senior authors.

**References**

1. Starup-Linde J, Rosendahl SB, Storgaard M, Langdahl B. Management of Osteoporosis in Patients Living with HIV - A Systematic Review and Meta-analysis. J Acquir Immune Defic Syndr. 2020;83(1):1–8.

2. Kanis JA, Johansson H, Oden A, Mccloskey E V. Assessment of fracture risk. Eur J Radiol. 2009;71:392–7.

3. Gregson CL, Hartley A, Majonga E, McHugh G, Crabtree N, Rukuni R, et al. Older age at initiation of antiretroviral therapy predicts low bone mineral density in children with perinatally-infected HIV in Zimbabwe. Bone [Internet]. 2019;125(May):96–102. Available from: https://doi.org/10.1016/j.bone.2019.05.012

4. Shiau S, Yin MT, Strehlau R, Patel F, Mbete N, Kuhn L, et al. Decreased bone turnover in HIV-infected children on antiretroviral therapy. Arch Osteoporos. 2018;13(1).

5. Arpadi SM, Shiau S, Strehlau R, Patel F, Mbete N, McMahon DJ, et al. Efavirenz is associated with higher bone mass in South African children with HIV. AIDS. 2016;30:2459–67.

6. Mukwasi-Kahari C, Rehman AM, Ó Breasail M, Rukuni R, Madanhire T, Chipanga J, et al. Impaired Bone Architecture in Peripubertal Children With HIV, Despite Treatment With Antiretroviral Therapy: A Cross-Sectional Study From Zimbabwe. J Bone Miner Res. 2023;38(2):248–60.

7. Rukuni R, Rehman AM, Mukwasi-Kahari C, Madanhire T, Kowo-Nyakoko F, McHugh G, et al. Effect of HIV infection on growth and bone density in peripubertal children in the era of antiretroviral therapy: a cross-sectional study in Zimbabwe. Lancet Child Adolesc Heal [Internet]. 2021;5(8):569–81. Available from: http://dx.doi.org/10.1016/S2352-4642(21)00133-4

8. UNAIDS. UNAIDS DATA 2019. UNAIDS. 2019;JC2959E:1–471.

9. M Arpadi S. Bone Health in HIV-Infected Children, Adolescents and Young Adults: A Systematic Review. J AIDS Clin Res. 2014;05(11).

10. Shiau S, Yin MT, Strehlau R, Burke M, Patel F, Kuhn L, et al. Deficits in Bone Architecture and Strength in Children Living With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2020;84(1):101–6.

11. Bonnick S Lou. Bone densitometry in clinical practice, Application and Intepretation. Second Edition. Humana Express, Totowa, New Jersey. 2002. 1–406 p.

12. Mchugh G, Rylance J, Mujuru H, Paeds M, Epi C, Bandason T, et al. Chronic Morbidity Among Older Children and Adolescents at Diagnosis of HIV Infection. J Acquir Immune Defic Syndr. 2016;73(3):275–81.

13. Rukuni R, Gregson C, Kahari C, Kowo F, Mchugh G, Munyati S, et al. The IMpact of Vertical HIV infection on child and Adolescent SKeletal development in Harare , Zimbabwe ( IMVASK Study ): a protocol for a prospective cohort study. BMJ Open. 2020;10:1–10.

14. Craig CL, Marshall AL, Sjo M, Sallis JF, Oja P. International Physical Activity Questionnaire : 12-Country Reliability and Validity. Med Sci Sport Exerc. 2003;35:1381–95.

15. Filteau S, Rehman AM, Yousafzai A, Chugh R, Kaur M, Sachdev HPS, et al. Associations of vitamin D status , bone health and anthropometry , with gross motor development and performance of school-aged Indian children who were born at term with low birth weight. BMJ Open. 2016;6:e009268.

16. FANTA. Developing and Validating Simple Indicators of Dietary Quality and Energy Intake of Infants and Young Children in Developing Countries: Summary of findings from analysis of 10 data sets. Food Nutr Tech Assist Proj [Internet]. 2006;1–99. Available from: https://www.fantaproject.org/sites/default/files/resources/IYCF\_Datasets\_Summary\_2006.pdf

17. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291–303.

18. Marshall WA, Tanner JM. Variations in the Pattern of Pubertal Changes in Boys. Arch Dis Childhood,. 1970;45:13–23.

19. Cole TJ, Freeman J V., Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med. 1998;17(4):407–29.

20. WHO. Growth reference data, weight-for-age(5 to 10years) https://www.who.int/tools/growth-reference-data-for-5to19-years/indicators/weight-for-age- 5to10-years. World Heal Organ. :19.

21. Arpadi SM. Growth failure in HIV - infected children. World Heal Organ Dep Nutr Heal Dev. 2005;Consultati(Durban, South Africa 10−13):1–20.

22. Adams JE, Engelke K, Zemel BS, Ward KA. Quantitative computer tomography in children and adolescents: The 2013 ISCD pediatric official positions. J Clin Densitom [Internet]. 2014;17(2):258–74. Available from: http://dx.doi.org/10.1016/j.jocd.2014.01.006

23. Leonard MB. A structural approach to the assessment of fracture risk in children and adolescents with chronic kidney disease. Pediatr Nephrol. 2007;22:1845–1824.

24. Gabel L, Macdonald HM, McKay HA. Sex Differences and Growth-Related Adaptations in Bone Microarchitecture, Geometry, Density, and Strength From Childhood to Early Adulthood: A Mixed Longitudinal HR-pQCT Study. J Bone Miner Res. 2017;32(2):250–63.

25. Fox AM. The HIV-poverty thesis RE-examined: Poverty, wealth or inequality as a social determinant of hiv infection in sub-Saharan Africa? J Biosoc Sci. 2012;44(4):459–80.

26. Hayes AF. Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression Based Approach. The Guilford Press. 2018. 113–119 p.

27. Harvey NC, Mahon PA, Robinson SM, Nisbet CE, Javaid MK, Crozier SR, et al. Different indices of fetal growth predict bone size and volumetric density at 4 years of age. J Bone Miner Res. 2010;25(4):920–7.

28. Poda GG, Hsu CY, Chao JCJ. Malnutrition is associated with HIV infection in children less than 5 years in Bobo-Dioulasso City, Burkina Faso. Med (United States). 2017;96(21).

29. Feucht UD, Bruwaene L Van, Becker PJ, Kruger M. Growth in HIV-infected children on long-term antiretroviral therapy. Trop Med Int Heal. 2016;21(5):619–29.

30. Tekleab AM, Tadesse BT, Giref AZ, Shimelis D, Gebre M. Anthropometric improvement among HIV infected pre-school children following initiation of first line anti-retroviral therapy: Implications for follow up. PLoS One. 2016;11(12):1–14.

31. Joel DR, Mabikwa V, Makhanda J, Tolle MA, Anabwani GM, Ahmed SF. The prevalence and determinants of short stature in HIV-infected children. J Int Assoc Provid AIDS Care. 2014;13(6):529–33.

32. Mwiru RS, Spiegelman D, Duggan C, Seage GR, Semu H, Chalamilla G, et al. Growth among HIV-infected children receiving antiretroviral therapy in Dar es Salaam, Tanzania. J Trop Pediatr. 2014;60(3):179–88.

33. Mcgrath CJ, Nduati R, Richardson BA, Kristal AR, Mbori-ngacha D, Farquhar C, et al. The Prevalence of Stunting Is High in HIV-1 – Exposed Uninfected Infants in Kenya 1 – 3. 2012;

34. Sutcliffe CG, van Dijk JH, Munsanje B, Hamangaba F, Sinywimaanzi P, Thuma PE, et al. Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia: A cohort study. BMC Infect Dis [Internet]. 2011;11(1):54. Available from: http://www.biomedcentral.com/1471-2334/11/54

35. Omoni AO, Ntozini R, Evans C, Prendergast AJ, Moulton LH, Christian PS, et al. Child Growth According to Maternal and Child HIV Status in Zimbabwe. Pediatr Infect Dis J. 2017;36(9):869–76.

36. Ebissa G, Deyessa N, Biadgilign S. Impact of highly active antiretroviral therapy on nutritional and immunologic status in HIV-infected children in the low-income country of Ethiopia. Nutrition [Internet]. 2016;32(6):667–73. Available from: http://dx.doi.org/10.1016/j.nut.2015.12.035

37. Cames C, Pascal L, Diack A, Mbodj H, Ouattara B, Diagne NR, et al. Risk Factors for Growth Retardation in HIV-infected Senegalese Children on Antiretroviral Treatment: The ANRS 12279 MAGGSEN Pediatric Cohort Study. Pediatr Infect Dis J. 2017;36(4):e87–92.

38. Van Der weele T, Vansteelandt S. Mediation analysis with multiple mediators. Epidemiol Method. 2013;2(1):95–115.

**Table 1: Clinical characteristics and anthropometry of children living with and without HIV stratified by sex**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Males (n=213)** | | | **Females (n=206)** | | |
|  | **CWOH (n=113)** | **CWH (n=100)** | **p-value** | **CWOH (n=111)** | **CWH (n=95)** | **p-value** |
| **Baseline clinical characteristics** | | | | | | |
| Age, yrs, mean (SD) | 12.2 (2.4) | 12.5 (2.5) | 0.29 | 12.6 (2.5) | 12.1 (2.4) | 0.14 |
| Age group, % |  |  | 0.96 |  |  | 0.23 |
| 8 - 10yrs | 40 (35%) | 34 (34%) |  | 35 (32%) | 36 (38%) |  |
| 11 - 13yrs | 39 (35%) | 34 (34%) |  | 33 (30%) | 33 (35%) |  |
| 14 - 16 yrs | 34 (30%) | 32 (32%) |  | 43 (39%) | 26 (27%) |  |
| Tanner stage, % |  |  | 0.59 |  |  | <0.001 |
| Tanner 1 | 35 (31%) | 38 (38%) |  | 19 (17%) | 43 (45%) |  |
| Tanner 2 | 31 (27%) | 28 (28%) |  | 22 (20%) | 15 (16%) |  |
| Tanner 3 | 18 (16%) | 15 (15%) |  | 22 (20%) | 20 (21%) |  |
| Tanner 4 | 27 (24%) | 16 (16%) |  | 35 (32%) | 14 (15%) |  |
| Tanner 5 | 2 (2%) | 3 (3%) |  | 13 (12%) | 3 (3%) |  |
| Pubertal status, % |  |  | 0.26 |  |  | <0.001 |
| Early Puberty | 66 (58%) | 66 (66%) |  | 41 (37%) | 58 (61%) |  |
| Late Puberty | 47 (42%) | 34 (34%) |  | 70 (63%) | 37 (39%) |  |
| Socio-economic status, % |  |  | 0.009 |  |  | 0.077 |
| Low, Tertile 1 | 28 (25%) | 43 (43%) |  | 32 (29%) | 40 (42%) |  |
| Middle, Tertile 2 | 36 (32%) | 30 (30%) |  | 37 (33%) | 31 (33%) |  |
| High, Tertile 3 | 49 (43%) | 27 (27%) |  | 42 (38%) | 24 (25%) |  |
| Orphanhood, % |  |  | <0.001 |  |  | <0.001 |
| Not an orphan | 105 (93%) | 58 (58%) |  | 105 (95%) | 51 (54%) |  |
| One parent alive | 5 (4%) | 36 (36%) |  | 4 (4%) | 36 (38%) |  |
| Orphan | 3 (3%) | 6 (6%) |  | 2 (2%) | 8 (8%) |  |
| Physical Activity, % |  |  | 0.061 |  |  | 0.16 |
| Low, <600 | 37 (33%) | 43 (43%) |  | 43 (39%) | 49 (52%) |  |
| Moderate, 600 -3000 | 40 (35%) | 21 (21%) |  | 32 (29%) | 24 (25%) |  |
| High, >3000 | 36 (32%) | 36 (36%) |  | 36 (32%) | 22 (23%) |  |
| Calcium Intake, % |  |  | 0.98 |  |  | 0.81 |
| Low, <150 mg | 49 (43%) | 42 (42%) |  | 48 (43%) | 38 (40%) |  |
| Moderate, 150-299 mg | 24 (21%) | 22 (22%) |  | 24 (22%) | 24 (25%) |  |
| High, 300-449 mg | 40 (35%) | 36 (36%) |  | 39 (35%) | 33 (35%) |  |
| **Change in clinical characteristics during one year follow up** | | | | | | |
| Tanner stage | 55 (49%) | 61 (62%) | 0.072 | 65 (59%) | 63 (66%) | 0.32 |
| **Baseline Anthropometry** | | | | | | |
| Height, cm, mean(SD) | 146.2 (14.5) | 140.6 (12.1) | 0.003 | 147.7 (11.6) | 139.4 (13.0) | <0.001 |
| Height for age Z-score, mean (SD)**a** | -0.7 (1.0) | -1.7 (1.1) | <0.001 | -0.5 (1.1) | -1.5 (1.0) | <0.001 |
| Height for age Z-score, mean (SD)**b** | 0 (1.5) | -1.6 (1.6) | <0.001 | 0 (1.4) | -1.4 (1.5) | <0.001 |
| Stunting, % | 8 (7%) | 33 (33%) | <0.001 | 10 (9%) | 25 (26%) | <0.001 |
| Weight, kgs, mean (SD) | 37.1 (11.0) | 33.2 (7.7) | 0.004 | 42.8 (13.1) | 34.3 (10.3) | <0.001 |
| Weight for age Z-score, mean (SD) | -0.8 (1.0) | -1.6 (1.2) | <0.001 | -0.2 (1.1) | -1.3 (1.1) | <0.001 |
| Underweight, % | 12 (11%) | 29 (29%) | <0.001 | 7 (6%) | 19 (20%) | 0.003 |
| Body mass index, kg/cm² | 16.9 (2.2) | 16.5 (1.4) | 0.17 | 19.1 (3.8) | 17.2 (2.5) | <0.001 |
| Body mass index Z-scores, mean (SD) | -0.6 (1.0) | -0.8 (0.8) | 0.086 | 0.0 (1.2) | -0.6 (0.9) | <0.001 |
| Wasting, % | 9 (8%) | 7 (7%) | 0.79 | 3 (3%) | 7 (7%) | 0.12 |
| Tibia length, mm, mean (SD) | 341.7 (47.3) | 327.6 (36.1) | 0.017 | 344.7 (37.6) | 323.5 (39.2) | <0.001 |
| **Change in anthropometry** | | | | | | |
| Height, cm, mean (SD) | 5.0 (2.4) | 6.8 (4.7) | <0.001 | 3.7 (3.3) | 4.9 (3.0) | 0.005 |
| Weight, kgs, mean (SD) | 4.0 (2.4) | 4.3 (3.1) | 0.53 | 3.9 (3.5) | 4.1 (3.3) | 0.6 |
| Body mass index, kg/cm², mean (SD) | 0.7 (0.8) | 0.4 (0.8) | 0.029 | 0.9 (1.2) | 0.8 (1.3) | 0.83 |
| Tibia length, mm, mean (SD) | 20.3 (21.6) | 20.3 (13.2) | 0.980 | 18.3 (18.6) | 16.9 (17.6) | 0.59 |

CWH: Children living with HIV, CWOH: Children without HIV, SD (Standard Deviation), BMI (Body mass index), aHeight for age Z-score based on British reference data, bHeight for age Z-score based on internally generated reference data

**Table 2: pQCT bone outcomes of children living with and without HIV, stratified by sex**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Males (n=213)** | | | | **Females (n=206)** | | | |
| **Baseline** | **\*Mean (SD) CWOH (n=113)** | **\*Mean (SD) CWH (n=100)** | **\*\*Adjusted MD (95% CI)** | **p-value** | **\*Mean (SD) CWOH (n=111)** | **\*Mean (SD) CWH (n=95)** | **\*\*Adjusted MD (95% CI)** | **p-value** |
| 4% Trabecular density, mg/cm³ | 208.0 (42.1) | 197.3 (37.7) | -10.52 (-22.8 , 1.7) | 0.092 | 210.7 (31.5) | 198.5 (33.1) | -12.63 (-22.9 , -2.4) | 0.016 |
| 38% Cortical density, mg/cm³ | 1070.3 (33.5) | 1067.8 (37.1) | -3.56 (-14.4 , 7.3) | 0.518 | 1098.6 (45.7) | 1095.7 (40.2) | -8.21 (-21.9 , 5.5) | 0.239 |
| 4% Total Cross sectional area, mm² | 752.7 (230.2) | 679.2 (177.9) | -99.79 (-163.0 , -36.6) | 0.002 | 731.7 (171.1) | 661.1 (166.9) | -104.89 (-157.8 , -51.9) | <0.001 |
| 38% Total Cross sectional area, mm² | 341.79 (78.01) | 313.00 (64.35) | -39.04 (-60.9 , -17.2) | 0.001 | 330.25 (60.4) | 286.52 (57.6) | -51.18 (-69.8 , -32.5) | <0.001 |
| 38% Cortical thickness, mm | 3.8 (0.6) | 3.8 (0.6) | -0.13 (-0.3 , 0) | 0.153 | 3.8 (0.6) | 3.7 (0.6) | -0.18 (-0.4 , 0) | 0.062 |
| 38% Stress strain index, mm³ | 1162.0 (386.9) | 1021.3 (311.1) | -197.54 (-304.9 , -90.2) | <0.001 | 1124.0 (326.4) | 923.1 (284.2) | -241.28 (-338.3 , -144.3) | <0.001 |
| **Follow up** | **\*Mean (SD) CWOH (n=113)** | **\*Mean (SD) CWH (n=100)** | **\*\*Adjusted MD (95% CI)** | **p-value** | **\*Mean (SD) CWOH (n=111)** | **\*Mean (SD) CWH (n=95)** | **\*\*Adjusted MD (95% CI)** | **p-value** |
| 4% Trabecular density, mg/cm³ | 203.8 (34.5) | 192.1 (36.1) | -10.87 (-21.6 , -0.1) | 0.048 | 210.9 (33.1) | 196.2 (32.6) | -14.52 (-25.0 , -4.1) | 0.007 |
| 38% Cortical density, mg/cm³ | 1077.1 (38.8) | 1074.0 (38.8) | -4.80 (-16.8 , 7.2) | 0.429 | 1115.5 (45.6) | 1109.0 (39.2) | -11.17 (-24.7 , 2.4) | 0.106 |
| 4% Total Cross sectional area, mm² | 783.0 (221.8) | 728.9 (187.3) | -81.91 (-144.8 , -19.0) | 0.011 | 748.6 (152.7) | 685.0 (151.1) | -94.32 (-142.0 , -46.6) | <0.001 |
| 38% Total Cross sectional area, mm² | 368.1 (79.1) | 342.1 (70.0) | -36.31 (-59.2 , -13.5) | 0.002 | 346.6 (56.5) | 306.6 (57.5) | -48.16 (-66.1 , -30.2) | <0.001 |
| 38% Cortical thickness, mm | 4.0 (0.6) | 3.9 (0.7) | -0.17 (-0.4 , 0) | 0.074 | 4.0 (0.6) | 3.8 (0.6) | -0.21 (-0.4 , 0) | 0.033 |
| 38% Stress strain index, mm³ | 1306.8 (410.2) | 1175.6 (358.3) | -190.72 (-308.4 , -73.0) | 0.002 | 1229.4 (314.6) | 1034.3 (295.1) | -240.50 (-336.9 , -144.1) | <0.001 |
| **Change over 12 months** | **\*Mean (SD) CWOH (n=113)** | **\*Mean (SD) CWH (n=100)** | **\*\*Adjusted MD (95% CI)** | **p-value** | **\*Mean (SD) CWOH (n=111)** | **\*Mean (SD) CWH (n=95)** | **\*\*Adjusted MD (95% CI)** | **p-value** |
| 4% Trabecular density, mg/cm³ | -3.8 (19.5) | -4.4 (17.2) | -0.35 (-6.0 , 5.3) | 0.903 | 0.1 (13.4) | -2.1 (13.9) | -1.61 (-5.9 , 2.7) | 0.463 |
| 38% Cortical density, mg/cm³ | 6.2 (18.3) | 5.1 (18.4) | -1.90 (-7.6 , 3.8) | 0.508 | 14.8 (16.7) | 10.6 (14.5) | -3.61 (-8.6 , 1.4) | 0.157 |
| 4% Total Cross sectional area, mm² | 27.5 (65.9) | 41.3 (53.2) | 13.23 (-5.3 , 31.8) | 0.161 | 15.7 (57.6) | 18.5 (61.8) | 6.42 (-12.4 , 25.3) | 0.503 |
| 38% Total Cross sectional area, mm² | 24.7 (15.7) | 24.7 (18.6) | 0.10 (-5.2 , 5.4) | 0.970 | 14.6 (16.4) | 16.4 (17.0) | 1.44 (-3.8 , 6.7) | 0.590 |
| 38% Cortical thickness, mm | 0.2 (0.2) | 0.1 (0.2) | -0.05 (-0.1 , 0) | 0.101 | 0.2 (0.2) | 0.1 (0.2) | -0.04 (-0.1 , 0) | 0.252 |
| 38% Stress strain index, mm³ | 136.5 (77.9) | 130.8 (95.6) | -7.12 (-33.7 , 19.5) | 0.599 | 94.2 (73.5) | 90.4 (89.8) | -6.52 (-32.2 , 19.2) | 0.617 |

**\**Unadjusted, \*\*Adjusted for socioeconomic status and orphanhood CWH: Children living with HIV, CWOH: Children without HIV, SD (Standard Deviation)***

***MD (95% CI); Mean Difference (95 % Confidence Interval) with CWOH as the reference group, such that negative values mean that those with HIV have lower values than those with HIV***

**Table 3: pQCT bone outcomes of children living with and without HIV, stratified by sex and pubertal status**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Unadjusted (n=419)** | | | | | **\*Adjusted (n=419)** | | | | | |
| **Males (n=213)** | **Tanner Stages 1 and 2** | | **Tanner Stages 3, 4 & 5** | | **Interaction** | **Tanner Stages 1 and 2** | | | **Tanner Stages 3, 4 & 5** | | **Interaction** |
| **Characteristic** | **MD (95% CI)** | **p-value** | **MD (95% CI)** | **p-value** | **p-value** | **MD (95% CI)** | | **p-value** | **MD (95% CI)** | **p-value** | **p-value** |
| ∆ 4% Trabecular Density, mg/cm³ | -3.10 (-9.0, 2.8) | 0.298 | 3.59 (-5.6, 12.8) | 0.441 | **0.208** | -2.91 (-9.6, 3.7) | | 0.389 | 3.52 (-7.6, 14.7) | 0.531 | **0.174** |
| ∆ 38% Cortical Density, mg/cm³ | 3.49 (-2.1, 9.1) | 0.218 | -7.13 (-16.1, 1.9) | 0.118 | **0.051** | 3.05 (-3.2, 9.3) | | 0.337 | -6.77 (-17.5, 3.9) | 0.212 | **0.042** |
| ∆ 4% Total CSA, mm² | -4.17 (-23.4, 15.1) | 0.669 | 40.81 (12.0, 69.6) | 0.006 | **0.011** | -2.04 (-23.8, 19.7) | | 0.853 | 31.27 (-3.1, 65.6) | 0.074 | **0.013** |
| ∆ 38% Total CSA, mm² | -0.78 (-6.7, 5.1) | 0.792 | 0.89 (-6.9, 8.7) | 0.820 | **0.728** | -0.72 (-7.4, 5.9) | | 0.831 | 1.47 (-7.9, 10.8) | 0.754 | **0.728** |
| ∆ 38% Cortical Thickness, mm | -0.05 (-0.1, 0) | 0.185 | -0.03 (-0.1, 0.0) | 0.372 | **0.653** | -0.05 (-0.1, 0) | | 0.275 | -0.03 (-0.1, 0.1) | 0.480 | **0.713** |
| ∆ 38% Stress Strain Index, mm³ | -3.16 (-33.6, 27.3) | 0.838 | -4.41 (-41.0, 32.2) | 0.811 | **0.958** | -3.05 (-37.5, 31.3) | | 0.861 | 4.42 (-39.3, 48.1) | 0.841 | **0.966** |
| **Females (n=206)** | **Tanner Stages 1 and 2** | | **Tanner Stages 3, 4 & 5** | | **Interaction** | **Tanner Stages 1 and 2** | | | **Tanner Stages 3, 4 & 5** | | **Interaction** |
| **Characteristic** | **MD (95% CI)** | **p-value** | **MD (95% CI)** | **p-value** | **p-value** | **MD (95% CI)** | | **p-value** | **MD (95% CI)** | **p-value** | **p-value** |
| ∆ 4% Trabecular Density, mg/cm³ | 0.98 (-4.5, 6.5) | 0.723 | -4.53 (-10.0, 1.0) | 0.106 | **0.163** | 0.25 (-6.1, 6.6) | | 0.938 | -2.97 (-9.6, 3.6) | 0.374 | **0.144** |
| ∆ 38% Cortical Density, mg/cm³ | -1.98 (-8.6, 4.7) | 0.556 | -3.26 (-9.2, 2.7) | 0.278 | **0.781** | -1.65 (-9.3, 6.0) | | 0.669 | -0.49 (-7.6, 6.6) | 0.892 | **0.845** |
| ∆ 4% Total CSA, mm² | -14.76 (-40.5, 11.0) | 0.259 | -2.10 (-20.7, 16.5) | 0.824 | **0.444** | -17.88 (-47.2, 11.4) | | 0.229 | 1.72 (-20.9, 24.3) | 0.880 | **0.546** |
| ∆ 38% Total CSA, mm² | -6.51 (-13.4, 0.3) | 0.063 | 4.76 (-1.1, 10.6) | 0.110 | **0.013** | -7.04 (-14.9, 0.9) | | 0.080 | 3.32 (-3.7, 10.3) | 0.349 | **0.022** |
| ∆ 38% Cortical Thickness, mm | -0.09 (-0.2, 0.0) | 0.072 | 0.02 (-0.0, 0.1) | 0.501 | **0.064** | -0.11 (-0.2, 0) | | 0.061 | 0.02 (-0.1, 0.1) | 0.639 | **0.096** |
| ∆ 38% Stress Strain Index, mm³ | -31.62 (-66.2, 3.0) | 0.073 | 9.68 (-20.5, 39.9) | 0.526 | **0.072** | -37.27 (-76.9, 2.4) | | 0.065 | 9.57 (-26.7, 45.9) | 0.602 | **0.097** |
| ***\*Adjusted for socioeconomic status and orphanhood*** | | | | | | |
| ***MD (95% CI); Mean Difference (95 % Confidence Interval) with CWOH as the reference group, such that negative values mean that those with HIV have lower values than those with HIV***  ***CSA; Cross Sectional Area*** | | | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 4: pQCT bone outcomes of children living with and without HIV after mediation analysis with HIV as exposure, internally generated height for age Z-scores as the mediator and adjusted for SES and orphanhood status** | | | | |
|  | **Adjusted for SES and orphanhood status** | | | |
| **Males (n=213)** | **Direct effect of HIV on pQCT outcome, β (95% CI);p value** | **Effect of Height Z-score on pQCT bone outcome, β (95% CI);p value** | **Indirect effect of HIV on pQCT outcome, β (95% CI);p value** | **Total effect of HIV on pQCT outcome, β (95% CI);p value** |
| ∆ 4% trabecular density | 1.02(-0.57, 2.60);0.210 | 1.02(-4.95, 6.98);0.738 | -1.37(-3.56, 0.82);0.221 | -0.35(-5.94, 5.24);0.902 |
| ∆ 38% cortical density | 1.29(-4.55, 7.12);0.666 | 2.36(0.81, 3.91);0.003 | -3.19(-5.55, -0.82);0.008 | -1.90(-7.46, 3.65);0.502 |
| ∆ 4% total CSA | 7.56(-11.83, 26.95);0.445 | -4.20(-9.36, 0.95);0.110 | 5.67(-1.56, 12.90);0.124 | 13.2(-4.98, 31.44);0.154 |
| ∆ 38% total CSA | 0.48(-6.02, 6.215.06);0.864 | -0.43(-1.91, 1.04);0.565 | -0.58(-1.41, 2.58);0.567 | 0.10(-5.07, 5.28);0.969 |
| ∆ 38% cortical thickness | -0.07(-0.13, 0.01);0.047 | -0.01(-0.03, 0.01);0.241 | 0.01(-0.01, 0.04);0.251 | -0.05(-0.11, 0.01);0.095 |
| ∆ 38% SSI | -4.09(-32.10, 23.91);0.774 | 2.23(-5.21, 9.68);0.560 | -3.02(-13.12, 7.08);0.558 | -7.12(-33.28, 19.05);0.594 |
| **Females (n=206)** | **Direct effect of HIV on pQCT outcome, β (95% CI);p value** | **Effect of Height Z-score on pQCT bone outcome, β (95% CI);p value** | **Indirect effect of HIV on pQCT outcome, β (95% CI);p value** | **Total effect of HIV on pQCT outcome, β (95% CI);p value** |
| ∆ 4% trabecular density | 0.86(-3.66, 5.38);0.709 | 1.74(0.51, 2.96);0.005 | -2.47(-4.40, -0.55);0.012 | -1.61(-5.86, 2.64);0.457 |
| ∆ 38% cortical density | -0.35(-5.56, 4.86);0.896 | 2.28(0.87, 3.69);0.002 | -3.26(-5.54, -0.98);0.005 | -3.61(-8.53, 1.31);0.151 |
| ∆ 4% total CSA | 6.71(-13.31, 26.83);0.509 | 0.24(-5.18, 5.66);0.931 | -0.34(-8.08, 7.39);0.931 | 6.41(-12.10, 24.94);0.417 |
| ∆ 38% total CSA | 2.62(-2.95, 8.17);0.357 | 0.83(-0.68, 2.33);0.282 | -1.18(-3.37, 1.01);0.289 | 1.44(-3.72, 6.59);0.585 |
| ∆ 38% cortical thickness | -0.03(-0.09, 0.04);0.364 | 0.01(-0.01, 0.02);0.667 | -0.01(-0.03, 0.02);0.667 | -0.04(-0.10, 0.03);0.244 |
| ∆ 38% SSI | 9.24(--17.54, 36.03);0.499 | 11.02(3.78, 18.27);0.003 | -15.76(-27.34, -4.19);0.008 | -6.52(-31.75, 18.71);0.612 |
|  |  |  |  |  |
| **\*\*The effect of HIV on Zim height z-score at baseline, (β (95% CI);p value) was '-0.88 (-1.19, -0.57);<0.001 (males) and '-0.90(-1.24, -0.57);<0.001 (females)** | | | |  |
| **Direct effect is the pathway from HIV to the pQCT outcome** | |  |  |  |
| **The indirect effect is the pathway from HIV via Zim height for age Z-score at baseline to the pQCT outcome** | | |  |  |
| **The total effect is the sum of the direct and indirect effects** | |  |  |  |
| **\*Adjusted for socioeconomic status and orphanhood** | |  |  |  |
| **MD (95% CI); Mean Difference (95 % Confidence Interval) with CWOH as the reference group, such that negative values mean that those with HIV have lower values than those with HIV.**  **CSA; Cross Sectional Area** | | | | |
|  |  |  |  |  |
| Shaded area=Complete mediation |  |  |  |  |

**Figure 1: Unadjusted comparison of change in pQCT measured bone outcomes, over 12 months, between children living with and without HIV infection by sex and pubertal status**



***-Figure 1 above shows unadjusted comparison of change in pQCT measured bone outcomes, over 12 months, between children living with and without HIV infection by sex and pubertal status***

***-CWH: Children living with HIV, CWOH: Children without HIV, CSA: Cross sectional area, SSI: Stress strain index***

**Figure 2: Conceptualised diagram showing bone accrual in children with and without HIV**

***-Figure 2 above is a hypothesised diagram, hypothesising that CWH are pre-set at a lower trajectory than CWOH before the age of 8 years, accrue bone at the same rate as CWOH and may or may not catch-up after pubertal years***

***-CWH: Children living with HIV, CWOH: Children without HIV, CSA: Cross sectional area, SSI: Stress strain index***